What is Noble Financial's Estimate for TOI Q2 Earnings?

Key Points

• Noble Financial has estimated that Oncology Institute's Q2 2025 earnings per share (EPS) will be ($0.14), maintaining an "Outperform" rating with a price target of $8.00.
• Oncology Institute's stock experienced a 0.8% increase, opening at $3.68, with a notable range of a 52-week low of $0.13 and a high of $3.88.
• Insider sales saw Director Brad Hively reduce his holdings by approximately 76.61%, selling nearly 2 million shares, while total insider sales over the last 90 days amounted to over $13 million.

The Oncology Institute, Inc. (NASDAQ:TOI - Free Report) - Equities researchers at Noble Financial issued their Q2 2025 earnings per share estimates for Oncology Institute in a research report issued to clients and investors on Wednesday, July 23rd. Noble Financial analyst R. Leboyer forecasts that the company will earn ($0.14) per share for the quarter. Noble Financial has a "Outperform" rating and a $8.00 price target on the stock. Noble Financial also issued estimates for Oncology Institute's Q3 2025 earnings at ($0.14) EPS, Q4 2025 earnings at ($0.12) EPS, FY2025 earnings at ($0.50) EPS, Q1 2026 earnings at ($0.08) EPS, Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.06) EPS, Q4 2026 earnings at ($0.06) EPS and FY2026 earnings at ($0.28) EPS.

Oncology Institute (NASDAQ:TOI - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.18) EPS for the quarter. The business had revenue of $104.41 million during the quarter. Oncology Institute had a negative net margin of 15.38% and a negative return on equity of 445.02%.

Other analysts have also recently issued reports about the stock. B. Riley initiated coverage on shares of Oncology Institute in a research note on Wednesday, July 16th. They issued a "buy" rating and a $6.00 target price for the company. BTIG Research started coverage on shares of Oncology Institute in a research report on Thursday, May 15th. They set a "buy" rating and a $7.00 price objective for the company.

Oncology Institute Stock Performance

Shares of TOI traded up $0.09 during mid-day trading on Monday, hitting $3.77. 2,748,070 shares of the company's stock were exchanged, compared to its average volume of 2,078,392. The company has a debt-to-equity ratio of 14.58, a current ratio of 1.79 and a quick ratio of 1.59. Oncology Institute has a fifty-two week low of $0.13 and a fifty-two week high of $4.04. The business's 50 day moving average is $2.84 and its two-hundred day moving average is $1.91.

Insider Buying and Selling

In other Oncology Institute news, Director Brad Hively sold 1,976,137 shares of Oncology Institute stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $2.87, for a total transaction of $5,671,513.19. Following the transaction, the director directly owned 603,501 shares of the company's stock, valued at $1,732,047.87. The trade was a 76.61% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Growth I. L.P. M33 sold 1,796,468 shares of the company's stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $2.71, for a total value of $4,868,428.28. Following the completion of the sale, the director directly owned 14,624,233 shares of the company's stock, valued at approximately $39,631,671.43. This represents a 10.94% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 4,726,137 shares of company stock valued at $13,379,013. 8.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in TOI. XTX Topco Ltd boosted its stake in Oncology Institute by 49.5% during the first quarter. XTX Topco Ltd now owns 55,698 shares of the company's stock worth $63,000 after buying an additional 18,448 shares during the last quarter. Citizens Financial Group Inc. RI acquired a new stake in shares of Oncology Institute in the 1st quarter valued at approximately $71,000. Kingswood Wealth Advisors LLC purchased a new position in Oncology Institute during the second quarter worth $132,000. WealthShield Partners LLC purchased a new stake in shares of Oncology Institute in the first quarter valued at $80,000. Finally, Goldman Sachs Group Inc. acquired a new position in Oncology Institute in the first quarter valued at $131,000. 36.86% of the stock is owned by institutional investors and hedge funds.

About Oncology Institute

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.